Scarica l'app Stockscreener
3.82
2.69%
0.10
Dopo l'orario di chiusura:
3.82
Precedente Chiudi:
$3.72
Aprire:
$3.85
Volume 24 ore:
87,230
Relative Volume:
0.45
Capitalizzazione di mercato:
$83.34M
Reddito:
-
Utile/perdita netta:
$-69.87M
Rapporto P/E:
-1.1904
EPS:
-3.2089
Flusso di cassa netto:
$-61.75M
1 W Prestazione:
+9.77%
1M Prestazione:
-16.41%
6M Prestazione:
-71.10%
1 anno Prestazione:
-66.10%
Intervallo 1D:
$3.645
$3.95
Intervallo di 1 settimana:
$3.40
$4.10
Portata 52W:
$3.35
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Nome
Aardvark Therapeutics Inc
Settore
Industria
Telefono
(858) 225-7696
Indirizzo
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
3.82 | 83.77M | 0 | -69.87M | -61.75M | -3.2089 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2026-03-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-03-02 | Downgrade | Stifel | Buy → Hold |
| 2026-01-28 | Iniziato | B. Riley Securities | Buy |
| 2025-12-23 | Iniziato | Oppenheimer | Outperform |
| 2025-12-12 | Iniziato | William Blair | Outperform |
| 2025-12-03 | Iniziato | Raymond James | Strong Buy |
| 2025-11-07 | Iniziato | BTIG Research | Buy |
| 2025-09-29 | Iniziato | Stifel | Buy |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Iniziato | BofA Securities | Buy |
| 2025-03-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Iniziato | Morgan Stanley | Overweight |
| 2025-03-10 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aardvark Therapeutics Inc Borsa (AARD) Ultime notizie
Aardvark Therapeutics Inc. (AARD) Gains 7% as Stock Approaches Resistance LevelRisk Reward Setups - newsline.com
Aardvark Therapeutics Implements Executive Retention Bonus Agreements - TipRanks
Executive retention bonuses outlined at Aardvark Therapeutics (NASDAQ: AARD) - Stock Titan
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - PR Newswire
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc.AARD - FinancialContent
Aardvark Therapeutics Insiders Lose Out As Stock Sinks To US$3.59 - simplywall.st
AARD Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Risk Report - newsline.com
Aardvark Therapeutics (AARD) Slips 2.45% as Stock Tests Key Support at $3.41Elliott Wave Entry - newsline.com
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits
Aardvark Therapeutics (AARD) Declines Over 4% as Stock Tests Key Support LevelsVolatility Skew - newsline.com
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid - GlobeNewswire
AARD Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue StageGAAP Earnings Report - The Legal Advocate
AARD Q1 2026 Earnings: EPS Misses Estimates but Stock Rises on Pipeline ProgressEPS Revision Trend - The Legal Advocate
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS - Moomoo
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News - Yahoo Finance
Aardvark Therapeutics(AARD) Stock Options Chain | Quotes & News - Moomoo
AARD Stock Price, Quote & Chart | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
AARD Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressAnalyst Drop Coverage - The Legal Advocate
AARD stock crashes 34% – here’s why this analyst finds it ‘hard to lean into’ Aardvark at this stage - MSN
Aardvark Therapeutics faces investigation after FDA halts its Phase 3 trial, causing stock to plunge. - Pluang
Aardvark Therapeutics shares plunge 56% after halting Phase 3 trial due to safety concerns. - Pluang
We're Keeping An Eye On Aardvark Therapeutics' (NASDAQ:AARD) Cash Burn Rate - Moomoo
FDA halts Aardvark Therapeutics rare disease study - MSN
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - Barchart.com
FDA halts Aardvark Therapeutics' ARD-101 trial over heart safety concerns, stock now valued mainly for cash. - Pluang
Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path Forward (NASDAQ:AARD) - Seeking Alpha
AARD stock plummets after hours as cardiac safety concerns trigger FDA hold on late-stage program - MSN
FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4 - TipRanks
Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Sahm
Aardvark Therapeutics downgraded to Underperform from Buy at BofA - TipRanks
Under FDA Clinical Hold, Aardvark Therapeutics Seeks Path Forward for Metabolic Drug - MedCity News
Aardvark Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.3, Implies 187% Upside - TradingView
B. Riley Adjusts Aardvark Therapeutics Price Target to $7 From $8, Maintains Buy Rating - Moomoo
Aardvark plummets on FDA clinical hold on Prader-Willi Syndrome asset - Seeking Alpha
Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application - Moomoo
AARD Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Aardvark Therapeutics Could Regain Investor Interest With Upcoming Results -- Market Talk - Moomoo
AARD Stock Crashes 34% – Here’s Why This Analyst Finds It ‘Hard To Lean Into’ Aardvark At This Stage - Stocktwits
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
FDA puts clinical hold on Aardvark’s IND - The Pharma Letter
Aardvark Therapeutics, Inc.Common Stock (Nasdaq:AARD) Stock Quote - The Chronicle-Journal
FDA Halts Aardvark Therapeutics Rare Disease Study - Benzinga
AARD Downgraded by Morgan Stanley -- Price Target Lowered to $3. - GuruFocus
FDA Places Full Hold On Aardvark’s ARD-101 Months After Voluntary Safety Pause - Citeline News & Insights
B. Riley Securities Maintains Aardvark Therapeutics(AARD.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
BTIG downgrades Aardvark Therapeutics stock rating on FDA hold By Investing.com - Investing.com Australia
Aardvark Therapeutics stock tumbles on FDA clinical hold, analyst downgrades - Investing.com Australia
Aardvark Therapeutics Inc Azioni (AARD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aardvark Therapeutics Inc Azioni (AARD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Dec 11 '25 |
Buy |
14.48 |
7,000 |
101,395 |
1,551,613 |
| Lee Tien-Li | Chief Executive Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,229 |
5,211 |
1,544,613 |
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):